Built and managed a senior team with extensive experience in manufacturing, development, clinical operations, regulatory, commercial, and basic research. The team has selected three immuno-oncology targets and two infectious disease targets, designed pre-clinical trials, and is preparing an IND in its lead indication.Voltron Therapeutics, Inc. is developing and optimizing a novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and Emerging Infectious Diseases. This technology was developed at the Vaccine and Immunotherapy Center at Massachusetts General Hospital. The platform consists of a stable immune activating component base that self assembles with biotinylated antigen targeting peptides. The Voltron team has created a modular vaccine platform where peptide components can be changed instantly to train the immune system to hunt for new targets. This robust and flexible vaccine platform can be instantly leveraged to address tumors, patient specific tumors, and local and global EIDs such as COVID, SARs or Ebola. The vaccine’s key characteristics include 100-day development, broader immune targeting, initiating both innate and cellular immune responses, improved durability of protection, flexibility/ ability to respond to mutations / variants of concern, and easy distribution and storage.Voltron holds an exclusive worldwide license to this technology.

Responsible for building a team with expertise in Artificial Intelligence, imaging technologies, pathology, diagnostics/prognostics, drug development, licensing and clinical/commercial operations. Developed business plan leveraging initial proof of concept research for speed to market in therapeutic areas of high need. Further, the company’s efforts are designed to lead to specific drug/treatment recommendations for patients and to identify biomarkers critical to drug development.PD Theranostics (PDTx) is focused on refining, expanding, and integrating the data that various imaging modalities can provide, greatly enhancing the current morphological assessment of tissue samples. This will allow PDTx to pinpoint the current state of specific cellular structures and predict how they are expected to change over time, providing a leading ‘prognosis’ indicator - versus today’s lagging ‘diagnosis’ indicator. PDTx is optimizing and standardizing its proprietary prognostic imaging workflows and predictive artificial intelligence (AI) algorithms to enhance existing pathology results and provide novel data designed to drive clinical decisions. This includes the potential to guide treatment recommendations centered on specific targeted therapies and their efficacy in human disease states, including cancer, infectious diseases and complications of diabetes, including diabetic foot ulcers. This information, which may allow healthcare providers to better tailor treatments for their patients, is currently unavailable.PDTx’s approach could be applied to any disease in which diagnosis rests on the histopathological analysis of tissue biopsies.

Responsible for portfolio product, technology and company identification and deal presentation/execution for Laidlaw Venture Partners (LVP). Additionally, provide strategic and operational direction for companies across the entire portfolio. LVP is the venture and private equity financing and portfolio operations arm of Laidlaw Ltd. The Partners at LVP have extensive experience in funding and operating healthcare technologies at various stages of development, across geographies and therapeutic areas. The team’s expertise includes C level healthcare operations and management, establishing and developing companies/teams, investment banking, venture formation, strategic business development, equity research, equity sales, as well as public and private financing.

Frequent interaction with institutional investors, C-level corporate executives, KOL's and industry sources. Additional responsibilities include business development, helping to establish marketing/event plans, and create additional revenue channels.

Member of the board of directors for BioSig Technologies, a medical technology company that is developing a proprietary technology platform in the electrophysiology space. The PURE EP System provides a clean, detailed signal that potentially will lead to better outcomes in atrial fibrillation and ventricle tachycardia procedures.

Algorithm Sciences is focused on improving the treatment of patients with pulmonary arterial hypertension (PAH). The Company is focused on a new platform that could provide a highly potent drug with less frequent dosing to patients. The company is preparing to potentially move into Phase 3 studies in 2020.

Cingulate Therapeutics is a clinical stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s disruptive, proprietary Precision Timed Release (PTR) drug delivery platform. Cingulate has developed an Erosion Barrier Layer technology that enables the creation of once-daily multi-dose tablets. These novel technologies are the backbone of the companies first two potential products for the treatment of ADHD.

Member of the board of directors for Evermore Global Advisors, a global special situations money manager.

Advisor to CHD Biosciences, a novel antimicrobial company. Role included strategic planning and business development.

Kinex is a specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory diseases. Kinex utilized its proprietary platform technologies Mimetica™ and Opal™ to discover new compounds and to build a pipeline of drug candidates with unique mechanisms that address unmet medical needs with large market potential.The company has significant operations in both the US and China.

Built healthcare and industrial boutique institutional reserach firm from 0 to 100+ clients. Achieved Institutional Investor status. Worked closely with CEOs, CFOs, and a variety of proprietary contacts to develop market and investment cases.